The Administration/Communication Core (Core A) is responsible for facilitating the coordination and oversight of all Program activities and for disseminating information within the SPORE and for external interactions. The Core is designed for low-cost, yet efficient administration and communication in order to focus funds on research activities. This core includes a basic science director (Dr. T.-C. Wu) and a clinical research director (Dr. Edward Partridge). Dr. Wu is responsible for coordinating basic scientific efforts and the coordination of individual projects. Dr. Partridge oversees patient identification, enrollment, and patient monitoring in the context of the Core. The administrative component of the Core follows an organizational diagram for management activities. Monitoring of research will occur via 1) Research Project Teams, 2) Committee of Research Project Leaders, 3) Core Investigators Committee, 4) Developmental Research Projects Program, 5) Career Development Committee, and 6) the central SPORE Steering Committee. Furthermore, the Internal and External Advisory Boards provide formal evaluations and reports to the Steering Committee. This resource funds a Clinical Research Coordinator who interacts with the other cores as well as with personnel from each individual project to ensure that all patient information, specimens, and results are properly collected and recorded in the computerized database. Core A also funds a patient advocate, who provides invaluable feedback on various SPORE activities from a unique perspective. Appropriate monitoring of patient safety, adverse events, and data management and confidentiality will be provided by the data safety monitoring boards. The communication component of the Core is directed at intra-SPORE, inter-SPORE, and National Cancer Institute research activities. The Core coordinates essential Program interactions including preparing applications and progress reports for the SPORE, all planning and evaluation activities, arranging and publicizing SPORE activities, coordinating advisory committee meetings, producing annual reports and performing analysis of budgetary matters.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA098252-11
Application #
8747918
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
2003-09-30
Project End
2019-08-31
Budget Start
2014-09-24
Budget End
2015-08-31
Support Year
11
Fiscal Year
2014
Total Cost
$234,986
Indirect Cost
$49,360
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Wang, Joshua W; Hung, Chein-Fu; Huh, Warner K et al. (2015) Immunoprevention of human papillomavirus-associated malignancies. Cancer Prev Res (Phila) 8:95-104
Banet, Natalie; Gown, Allen M; Shih, Ie-Ming et al. (2015) GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol 39:101-8
Wu, Chao-Yi; Yang, Li-Hua; Yang, Huang-Yu et al. (2014) Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 20:644-57
Zhao, Rui-Xun; Xu, Zhi-Xiang (2014) Targeting the LKB1 tumor suppressor. Curr Drug Targets 15:32-52
Kwak, Kihyuck; Jiang, Rosie; Wang, Joshua W et al. (2014) Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types. PLoS One 9:e97232
Coughlin, Kathleen; Anchoori, Ravi; Iizuka, Yoshie et al. (2014) Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20:3174-86
Wang, Joshua W; Jagu, Subhashini; Wang, Chenguang et al. (2014) Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions. PLoS One 9:e101576
Paul, Proma; Tanner, Amanda E; Gravitt, Patti E et al. (2014) Acceptability of HPV vaccine implementation among parents in India. Health Care Women Int 35:1148-61
Soong, Ruey-Shyang; Song, Liwen; Trieu, Janson et al. (2014) Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors. PLoS One 9:e93162
Zhang, Huang-Ge; Grizzle, William E (2014) Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 184:28-41

Showing the most recent 10 out of 188 publications